Table 3 Data at randomization for simulation 2A
From: Preventing false discovery of heterogeneous treatment effect subgroups in randomized trials
Placebo | Treatment | ASD | |
|---|---|---|---|
n = 3000 | n = 3000 | ||
Age (years) | 68.1 (±10.1) | 68.1 (±10.0) | 0 |
Black race | |||
No | 2133 (71.1%) | 2075 (69.2%) | 0.04 |
Yes | 867 (28.9%) | 925 (30.8%) | 0.04 |
Systolic blood pressure (mm Hg) | 140.8 (±15.1) | 140.1 (±15.1) | 0.05 |
Diastolic blood pressure (mm Hg) | 78.1 (±11.8) | 77.7 (±11.9) | 0.04 |
Serum creatinine (mg/dl) | 1.1 (±0.3) | 1.1 (±0.3) | 0.06 |
Estimated GFR (ml/min/1.73 m2) | 72.2 (±19.6) | 72.0 (±20.0) | 0.01 |
Statin use | |||
No | 1706 (56.9%) | 1745 (58.2%) | 0.03 |
Yes | 1294 (43.1%) | 1255 (41.8%) | 0.03 |
Aspirin use | |||
No | 1446 (48.2%) | 1410 (47.0%) | 0.02 |
Yes | 1554 (51.8%) | 1590 (53.0%) | 0.02 |
Framingham risk score | 25.2 (±12.2) | 25.2 (±11.9) | 0 |
Smoking status | |||
Never | 1350 (45.0%) | 1348 (44.9%) | 0 |
Former | 1244 (41.5%) | 1220 (40.7%) | 0.02 |
Current | 406 (13.5%) | 432 (14.4%) | 0.03 |